Literature DB >> 24331797

Body fluid biomarkers in multiple sclerosis.

Manuel Comabella1, Xavier Montalban2.   

Abstract

Biomarkers can be thought of as multifaceted indicators of healthy status or of pathological disorders. The study of multiple sclerosis can benefit from the use of biomarkers because of the disease's inherent heterogeneity. Biomarkers in multiple sclerosis might assist with diagnosis, prediction of disease course, or identification of response outcome to treatments. Despite the need for biomarkers and extensive research to identify them, validation and clinical application of biomarkers is still an unmet need in multiple sclerosis, and large gaps remain between exploratory biomarkers proposed in many studies, validated biomarkers, and biomarkers that are integrated into routine clinical practice.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24331797     DOI: 10.1016/S1474-4422(13)70233-3

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  73 in total

Review 1.  Body fluid biomarkers for multiple sclerosis--the long road to clinical application.

Authors:  Charlotte E Teunissen; Arjan Malekzadeh; Cyra Leurs; Claire Bridel; Joep Killestein
Journal:  Nat Rev Neurol       Date:  2015-09-22       Impact factor: 42.937

2.  Predicting therapeutic response to fingolimod treatment in multiple sclerosis patients.

Authors:  Bibiana Quirant-Sánchez; José V Hervás-García; Aina Teniente-Serra; Luis Brieva; Ester Moral-Torres; Antonio Cano; Elvira Munteis; María J Mansilla; Silvia Presas-Rodriguez; Juan Navarro-Barriuso; Cristina Ramo-Tello; Eva M Martínez-Cáceres
Journal:  CNS Neurosci Ther       Date:  2018-04-15       Impact factor: 5.243

Review 3.  The tension between early diagnosis and misdiagnosis of multiple sclerosis.

Authors:  Andrew J Solomon; John R Corboy
Journal:  Nat Rev Neurol       Date:  2017-08-11       Impact factor: 42.937

4.  CSF-PR 2.0: An Interactive Literature Guide to Quantitative Cerebrospinal Fluid Mass Spectrometry Data from Neurodegenerative Disorders.

Authors:  Astrid Guldbrandsen; Yehia Farag; Ann Cathrine Kroksveen; Eystein Oveland; Ragnhild R Lereim; Jill A Opsahl; Kjell-Morten Myhr; Frode S Berven; Harald Barsnes
Journal:  Mol Cell Proteomics       Date:  2016-11-27       Impact factor: 5.911

Review 5.  Multiple sclerosis.

Authors:  Massimo Filippi; Amit Bar-Or; Fredrik Piehl; Paolo Preziosa; Alessandra Solari; Sandra Vukusic; Maria A Rocca
Journal:  Nat Rev Dis Primers       Date:  2018-11-08       Impact factor: 52.329

6.  Prevalence and predictors of blood-brain barrier damage in the HAART era.

Authors:  A Calcagno; M C Alberione; A Romito; D Imperiale; V Ghisetti; S Audagnotto; F Lipani; S Raviolo; G Di Perri; S Bonora
Journal:  J Neurovirol       Date:  2014-06-28       Impact factor: 2.643

Review 7.  Genomic, proteomic, and systems biology approaches in biomarker discovery for multiple sclerosis.

Authors:  Carol Chase Huizar; Itay Raphael; Thomas G Forsthuber
Journal:  Cell Immunol       Date:  2020-09-20       Impact factor: 4.868

8.  Protein aggregate formation permits millennium-old brain preservation.

Authors:  Axel Petzold; Ching-Hua Lu; Mike Groves; Johan Gobom; Henrik Zetterberg; Gerry Shaw; Sonia O'Connor
Journal:  J R Soc Interface       Date:  2020-01-08       Impact factor: 4.118

Review 9.  Biomarkers in Multiple Sclerosis.

Authors:  Anu Paul; Manuel Comabella; Roopali Gandhi
Journal:  Cold Spring Harb Perspect Med       Date:  2019-03-01       Impact factor: 6.915

Review 10.  Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients.

Authors:  Harald Hegen; Michael Auer; Florian Deisenhammer
Journal:  Drugs       Date:  2016-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.